Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society of Thoracic Surgeons.
ATLANTA, Jan. 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society of Thoracic Surgeons. The publication, titled Low-Dose Versus Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Controlled Trial, https://www.annalsthoracicsurgery.org/article/S0003-4975(22)00138-2/fulltext, highlighted outcomes from the multicenter, non-inferiority, two-arm study which assessed whether, after an On-X mechanical mitral valve replacement (MVR), patients could be safely managed with lower-intensity warfarin plus aspirin. The results were published online on January 29, 2022. In tandem with the publication, the study results were presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons on January 30, 2022. “The PROACT Mitral results add to the data from clinical trials we have sponsored showing that patients with our On-X heart valves can be safely maintained with lower anticoagulation levels than required for competitors’ mechanical valves. We continue investing in scientific studies to improve and simplify the lives of prosthetic heart valve patients. In addition, the ongoing PROACT Xa trial aims to prove that patients with the On-X aortic valve can be safely maintained on apixaban, without the need for routine anticoagulation blood tests,” said Pat Mackin, Chairman, President and CEO of Artivion, Inc. Michael W. A. Chu, M.D., FRCSC, Chair/Chief of Cardiac Surgery at London Health Sciences Centre, Western University, London, ON, Canada, and lead author for the PROACT mitral clinical trial, said, “this randomized trial has very important and reassuring findings for patients with unrepairable mitral valve disease. Patients with an On-X mechanical mitral valve can be reassured that a lower INR target is safe, without any increased risk of blood clots or stroke, which may help to alleviate some of the concerns with anticoagulation management with a mechanical valve. We believe this research represents one of the most important advances in the clinical management of mechanical mitral valves over the past 2 decades and will potentially have important practice and guideline changing implications. We are proud to have presented it at the Society of Thoracic Surgeons’ Annual Meeting along with simultaneous publication in The Annals of Thoracic Surgery.” About the On-X Mechanical Heart Valve PROACT Trial About the On-X Mechanical Heart Valve About Artivion Contacts:
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-publication-of-on-x-mitral-heart-valve-proact-study-results-in-the-annals-of-thoracic-surgery-301471223.html SOURCE Artivion, Inc. | ||||||||||||
Company Codes: NYSE:AORT |